Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
Positive results from pioneering Salford Lung Study in asthma published in The Lancet, and presented at European Respiratory Congress
Relvar Ellipta was superior to usual care treatment in improving asthma control for patients in Salford Lung Study.
GSK exercises option on phase I/II NY-ESO T-cell therapy (GSK3377794)
Today GSK announced that it has exercised the option to obtain an exclusive global license from Adaptimmune
GSK presents respiratory data from pipeline to clinical practice at ERS
45 abstracts will be shared about current and future treatments for patients with respiratory diseases
GSK responds to UK Life Sciences Industrial Strategy
Read our response to the UK Life Sciences Industrial Strategy.
GSK delivers further progress in Q2 and sets out new priorities for the Group
Q2 was another quarter of progress for GSK with Group sales up 3% to £7.3 billion and Adjusted EPS of 27.2p.
Switching to a dolutegravir regimen from a boosted protease inhibitor regimen maintained viral suppression and improved lipid fractions in patients with HIV and high cardiovascular risk
ViiV Healthcare and NEAT-ID announced results from the NEAT 022 study of more than 400 patients with HIV and high cardiovascular risk
Karenann Terrell appointed Chief Digital & Technology Officer, GSK
GSK today announced that Karenann Terrell has been appointed Chief Digital & Technology Officer
ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings
ViiV, specialist HIV company, majority owned by GSK, Pfizer & Shionogi announced positive interim results from DAWNING.
GSK submits US regulatory filing of Arnuity Ellipta in children with asthma
The sNDA is seeking approval for a dose of 50mcg once-daily, delivered using the Ellipta inhaler in this group of patients.
Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen of long-acting cabotegravir and rilpivirine and a three-drug regimen in patients with HIV
LATTE-2 study results published in The Lancet and presented at International AIDS Society Meeting
GSK receives FDA approval for a new self-injectable formulation of Benlysta (belimumab) for systemic lupus erythematosus
GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta
GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA).
GSK announces Board and Committee changes
GSK - Dr Laurie Glimcher has been appointed to Board of the Company, Non-Executive Director and a Scientific and Medical Expert.
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017
GSK updates on UK manufacturing network
GSK today set out several announcements made by the company to improve the efficiency and competitiveness of its manufacturing network.
GSK announces US regulatory submission for mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
GSK plc announced the submission of a supplemental Biologics License Application (sBLA) to the United States Food and Drug Administration
GSK receives CHMP positive opinion for Synflorix pneumococcal vaccine four-dose vial
New presentation designed to significantly reduce storage requirements in developing countries.
GSK starts phase III study with mepolizumab in patients with nasal polyps
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a phase III study with mepolizumab, an interleukin 5 (IL-5) antagonist
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC’s Advisory Meeting
Study conducted in individuals who had previously received current standard of care
GSK announces results from 10-year continuation study showing sustained disease control with Benlysta (belimumab) in SLE
Benlysta is a biologic medicine specifically developed and approved for SLE